Last reviewed · How we verify
XR-NTX
At a glance
| Generic name | XR-NTX |
|---|---|
| Also known as | long-acting naltrexone, Vivitrol, extended-release naltrexone, Vivitrol® |
| Sponsor | University of California, Los Angeles |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder (PHASE3)
- Long-acting Naltrexone for Pre-release Prisoners (PHASE3)
- Extended Release Naltrexone Versus Extended Release Buprenorphine With Individuals Leaving Jail (PHASE2,PHASE3)
- Naltrexone in AUD Reward Drinkers (PHASE4)
- Optimizing Retention, Duration and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy (RDD) (PHASE2)
- Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) (PHASE2)
- The Youth Opioid Recovery Support (YORS) Intervention (NA)
- Emergency Department-Initiated Medications for Alcohol Use Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- XR-NTX CI brief — competitive landscape report
- XR-NTX updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI